Fujifilm sets aside manufacturing space for a possible Gates-funded COVID-19 therapy

Dozens of drug candidates are being floated as possible therapies for COVID-19, but manufacturing a successful candidate on a mass scale won't be easy. In a deal with a Bill Gates-funded drug accelerator, Fujifilm Diosynth is hoping to ease some of that production burden.

Fujifilm will devote some of its manufacturing capacity at its Denmark biologics plant for a treatment yet to be identified by the Gates-funded COVID-19 Therapeutics Accelerator, the drugmaker said Thursday.